Oxford Biomedica

Oxford Biomedica plc
Company typePublic company
IndustryPharmaceutical industry
Founded1995
HeadquartersOxford
Key people
Frank Mathias (CEO)
RevenueDecrease £89.5 million (2023)[1]
Decrease £(184.2) million (2023)[1]
Decrease £(184.2) million (2023)[1]
Websitehttps://oxb.com/

Oxford Biomedica (OXB) is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange.[2]

  1. ^ a b c "Annual Results 2023". Oxford Biomedica. Retrieved 29 April 2024.
  2. ^ "FTSE UK Index Series: Annual Review June 2020". 3 June 2020. Archived from the original on 3 June 2020. Retrieved 3 June 2020.